Study on Safety of Prabchompoothaweeb extract capsules in healthy volunteers

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

TCTR

Registry ID

TCTR20251220007

Enrollment

Registered

2025-12-20

Start date

2024-02-21

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

both sex of Healthy volunteers, age 20-60 years Healthy volunteers.

Interventions

Take Prabchompoothaweeb 300 mg per day. 1 capsule orally before meal 3 times per day for 6 weeks,Take Prabchompoothaweeb 600 mg per day. 2 capsule (100 mg per capsule) orally before meal 3 times per

Experimental Drug,Experimental Drug

Prabchompoothaweeb Extract,Prabchompoothaweeb capsule

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Age in range 20-60 years old 2. Healthy, or do not have serious medical conditions. 3. able to follow the instructions for 8 weeks

Exclusion criteria

Exclusion criteria: 1. Allergic reactions to Prabchompoothaweeb medications. 2. Take medication constantly. 3. Pregnant or lactating. 4. Participant in another study.

Design outcomes

Primary

Measure	Time frame
safety 6 weeks CBC , Liver function	—

Secondary

Measure	Time frame
safety 6 weeks Renal function, Lipid profiles	—

Countries

Thailand

Contacts

Public ContactDalicha Chungsiriporn

Thammasat University

dalicha168@gmail.com0819810568

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026